Article

Anterior chamber IOLs have evolved over time

There are many locations within the eye that an IOL can be placed. Most often, lenses are placed in the bag, but they may be placed in the sulcus, sewn into the posterior chamber, or sewn into or clipped onto the iris. Another location can be in the anterior chamber. Let's look at the evolution of anterior chamber IOLs (AC IOLs) in this month's column.

There are many locations within the eye that an IOL can be placed. Most often, lenses are placed in the bag, but they may be placed in the sulcus, sewn into the posterior chamber, or sewn into or clipped onto the iris. Another location can be in the anterior chamber. Let's look at the evolution of anterior chamber IOLs (AC IOLs) in this month's column.

Inflammation was an early problem with the implants; anti-inflammatory medications had yet to be developed. Pupillary occlusion and secondary glaucoma were not uncommon. Later complications included secondary membranes and lens dislocations, which occurred primarily due to the weight and size of the lens. By 1960, most AC IOLs were abandoned because of a cited 13% to 15% incidence of dislocations and an 8% to 10% incidence of glaucoma.

Some modifications Choyce's lenses were termed Mark lenses. The Mark was first implanted in 1956 as a modification of Strampelli's lens, and his Mark VIII lens was first implanted in 1963; this was his most used implant. It was a ridged, quadrangular lens having a 6-mm optic, four-point fixation, and a chord length of between 11 and 14 mm. Choyce used this lens for secondary implants in either extracapsular or intracapsular extractions.

Colored lenses were also used inpatients with albinism to minimize the iris transillumination.

In 1977 and 1978, a number of cases with complications of bleeding, elevated IOP, and iritis were reported in the literature. These reports increased, and a syndrome-the uveitis, glaucoma, and hyphema (UGH) syndrome-was described.

Related Videos
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.